CoChat

Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice

Open access
Bunin, Deborah I., Bakke, James, Green, Carol E., Javitz, Harold S., Fielden, Mark, Chang, Polly Y. · 2020 · International Journal of Radiation Biology

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Purpose: Rapid depletion of white blood cells, platelets, and reticulocytes are hallmarks of hematopoietic injury of acute radiation syndrome (H-ARS) and, if left untreated, can lead to severe health consequences including death. While the granulocyte colony stimulating factors (G-CSF) filgrastim (Neupogen®), pegfilgrastim (Neulasta®), and sargramostim (Leukine®) are approved to increase survival in patients exposed to a myelosuppressive dose of radiation, no medical countermeasure is currently available for treatment of the thrombocytopenia that also results following radiation exposure. Romiplostim (Nplate®), a thrombopoietin receptor agonist, is the first FDA-approved thrombopoiesis-stimulating protein for the treatment of low platelet (PLT) counts in adults with chronic immune thrombocytopenia. Herein, we present the results of an analysis in mice of romiplostim as a medical countermeasure to improve survival and PLT recovery following acute radiation.Materials and methods: Male and female C57BL/6J mice (11 − 12 weeks of age, n = 21/sex/group) were total body irradiated (TBI) with 6.8 Gy X-rays that reduces 30-day survival to 30% (LD70/30). Vehicle, romiplostim, and/or pegfilgrastim were administered subcutaneously beginning 24 h after TBI for 1–5 days. Evaluation parameters included 30-day survival, pharmacokinetics, and hematology.Results: Full or maximal efficacy with an ∼40% increase in survival was achieved after a single 30 µg/kg dose of romiplostim. No further survival benefit was seen with higher (100 µg/kg) or more frequent dosing (3 or 5 once daily doses at 30 µg/kg) of romiplostim or combined treatment with pegfilgrastim. Pharmacodynamic analysis revealed that the platelet nadir was not as low and recovery was faster in the irradiated mice treated with romiplostim when compared with irradiated control animals (Day 8 versus 10 nadir; Day 22 versus 29 recovery to near baseline). Platelet volume also increased more rapidly after romiplostim injection. Kinetic profiles of other hematology parameters were similar between TBI romiplostim-treated and control mice. Peak serum levels of romiplostim in TBI mice occurred 4 − 24 h (Tmax) after injection with a t1/2 of ∼24 h. Cmax values were at ∼6 ng/ml after 30 µg/kg ± TBI and ∼200 ng/ml after 300 µg/kg. A 10-fold higher romiplostim dose increased the AUClast values by ∼35-fold.Conclusion: A single injection of romiplostim administered 24 h after TBI is a promising radiation medical countermeasure that dramatically increased survival, with or without pegfilgrastim, and hastened PLT recovery in mice.

Overview

Integrity signals

Registry

Crossref · 10.1080/09553002.2019.1605465

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 2

  1. Levin J, 1982, Blood, 60, 989
  2. U.S. Department of Health and Human Services Press Office. 2016. HHS enhances nation's health preparedness for radiological threats. [updated October 6, 2016

Cited by

See all 60

Metadata

Authors
Bunin, D. I., Bakke, J., Green, C. E., Javitz, H. S., Fielden, M., & Chang, P. Y.
Affiliations
  • SRI International (US)
  • Amgen (United States) (US)
Corresponding author
Bunin, Deborah I.
Venue
International Journal of Radiation Biology
Published
2019-04-29
Volume
96
Issue
1
Pages
145-154
ISSN
  • 0955-3002 (ISSN-L)
  • 1362-3095
OpenAlex
W2941607887
Cited by
60
References
24
Citations by year
2026: 10 · 2025: 6 · 2024: 5 · 2023: 8 · 2022: 12 · 2021: 9 · 2020: 7 · 2019: 2
FWCI
4.99
Type
journal article
Language
en
Open access
Locations
  • International Journal of Radiation Biology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institue of Allergy and Infectious Diseases, National Institues of Health, Dept. of Health and Human Services (HHSN272201500013I)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords
romiplostim, radiation sickness, radiation countermeasures, thrombopoietin receptor agonists, thrombocytopenia, platelet recovery, total body irradiation, pegfilgrastim, hematopoietic damage, survival, pharmacokinetics, pharmacodynamics, platelet volume, mice
MeSH terms
Filgrastim, Medical Countermeasures, Animals, Blood Platelets, Dose-Response Relationship, Drug, Drug Interactions, Female, Male, Mice, Inbred C57BL, Platelet Count, Polyethylene Glycols, Receptors, Fc, Recombinant Fusion Proteins, Thrombopoietin, X-Rays, Survival Analysis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice. https://app.cochat.ai/papers/10.1080/09553002.2019.1605465
The paper
Bunin, D. I., Bakke, J., Green, C. E., Javitz, H. S., Fielden, M., & Chang, P. Y. (2020). Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice. International Journal of Radiation Biology. https://doi.org/10.1080/09553002.2019.1605465

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.